Drug Profile
Research programme: recombinant fusion proteins - Wyeth
Alternative Names: GPG 290; GPIb290/2V-IgLatest Information Update: 10 Aug 2009
Price :
$50
*
At a glance
- Originator Wyeth
- Class Glycoproteins; Recombinant fusion proteins
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Thrombosis